52423-70-8

Usage

Uses

Used in Pharmaceutical Industry:
2-(3-(4-Chlorophenyl)pyrrolidin-3-yl)ethanol is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure, including the pyrrolidine ring and 4-chlorophenyl group, may contribute to the development of new drugs with specific therapeutic properties.
Used in Chemical Research and Development:
2-(3-(4-Chlorophenyl)pyrrolidin-3-yl)ethanol serves as a valuable compound in chemical research, where it can be used to explore its reactivity, stability, and potential interactions with other molecules. This research can lead to a better understanding of its properties and the discovery of new applications in various chemical processes.

InChI:InChI=1S/C12H16ClNO/c13-11-3-1-10(2-4-11)12(6-8-15)5-7-14-9-12/h1-4,14-15H,5-9H2

Upstream product

• 660844-95-1 3-(4-chloro-phenyl)-3-(2-hydroxy-ethyl)-pyrrolidine-1-carboxylic acid ethyl ester 
• 40877-58-5 3-cyano-3-(4-chloro-phenyl)-pentanedioic acid diethyl ester 
• 140-53-4 p-chlorobenzyl cyanide 
• 51304-61-1 4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine hydrochloride 
• 660844-74-6 3-(4-Chloro-phenyl)-3-((E)-2-methoxy-vinyl)-pyrrolidine-1-carboxylic acid ethyl ester 
• 660844-94-0 3-(4-chlorophenyl)-3-(2-oxoethyl)pyrrolidine-1-carboxylic acid ethyl ester 
• 660844-90-6 6-(4-chlorophenyl)-7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylic acid ethyl ester 
• 660844-91-7 3-(4-chlorophenyl)-3-formylpyrrolidine-1-carboxylic acid ethyl ester 
• 660844-89-3 4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine-1-carboxylic acid ethyl ester 
• 40877-59-6 (3-(4-chloro-phenyl)-5-oxo-pyrrolidin-3-yl)acetic acid ethyl ester 

Downstream Products

• 52423-71-9 4-[3-(4-Chloro-phenyl)-3-(2-hydroxy-ethyl)-pyrrolidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one 
• 178371-50-1 2-[1-(3,4,5-trimethoxy-benzoyl)-3-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-methanesulfonate 

Relevant academic research and scientific papers

Design, Synthesis, and Evaluation of Metabolism-Based Analogues of Haloperidol Incapable of Forming MPP+-like Species

The long-term, irreversible, Parkinsonism-like side effects of haloperidol have been speculated to involve several mechanisms. More recently, it has been speculated that the metabolic transformation to MPP+-like species may contribute to the Parkinsonism-like side effects. Because BCPP+ and its reduced analogue have been shown to possess the potential to destroy dopamine receptors in the nigrostriatum, we have designed new analogues of haloperidol lacking the structural features necessary to form neurotoxic quaternary species but retaining their dopamine-binding capacity. The most potent agent at the D2 receptor, the homopiperidine analogue 11, was found to be equipotent to haloperidol. It was also of interest to identify analogues with DA binding profiles similar to that of clozapine at the dopamine receptor subtypes. Evaluation of the proposed agents shows that the ratio of D2 to D4 (2) binding of clozapine was mimicked by 7 [Ki(D2) = 33, Ki(D3) = 200, Ki(D4) = 11 nM; Ki(D2)/Ki(D4) = 3] and 9 [Ki(D2) = 44, Ki(D3) = 170, Ki(D4) = 24 nM; Ki(D2)/Ki(D4) = 2]. A preliminary in-vivo testing of compound 7 shows that its behavioral profile is similar to that of clozapine. This profile suggests that there is a need for further evaluation of these two synthetic agents and their enantiomers for efficacy and lack of catalepsy in animal models.

SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL)[1,4]DIAZEPANES USEFUL FOR THE TREATMENT ALLERGIC DISEASES

The present invention relates to novel 4-(1H-benzimidazol-2-yl)[1,4] diazepane derivatives of formula (1): and stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.

Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases

The present invention relates to novel 4-(1H-benzimidazol-2-yl)[1,4]diazepane derivatives of formula and stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.

Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease

The present invention relates to novel 4-(1H-benzimidazol-2-yl)[1,4]diazepane derivatives of formula (1): and stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.

Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases

The present invention relates to novel substituted piperidine derivatives of formula (1), stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.

Substituted piperidines useful for the treatment of allergic diseases

The present invention relates to novel substituted piperidine derivatives of the formula STR1stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic diseases including: seasonal rhinitis, allergic rhinitis, and sinusitis.

Substituted benzoylpiperidine derivatives and their use as Neurokinin antagonists

The present invention provides a compound of the formula:- or a pharmaceutically acceptable acid addition salt thereof, whereinAr is phenyl substituted by 1 or 2 substituent(s) each independently selected from fluoro and chloro;X is NSO2(C1-C4 alkyl), NSO2(halo(C1-C4 alkyl)) or O;m is 0 or 1 ;n is 1 or 2;p is 1 or 2;q is 1 or 2; and r is 1 or 2, together with processes for the preparation of, intermediates used in the preparation of, compositions containing and uses of, such derivatives. The compounds have tachykinin receptor antagonist activity.

Synthesis and structure-activity relationships for a series of substituted pyrrolidine NK1/NK2 receptor antagonists

We recently described the synthesis and characterization of MDL 105,212, a non peptide tachykinin antagonist with high affinity for NK1 and NK2 receptors. Here we report the synthesis and structure-activity relationships for a series of analogs of MDL 105,212 with regards to: NK1 and NK2 receptor binding affinity, physical-chemical characterization; in vitro absorption potential; in vitro metabolic stability; and efficacy in a capsaicin-challenge conscious guinea pig model after oral administration.